Background: It remains unclear whether concomitant or subsequent left atrial appendage closure (LAAC) may affect atrial fibrillation (AF) ablation outcomes.
Objective: To evaluate the impact of LAAC on AF recurrence and its role in clinical outcomes.
Methods: A sub-analysis was conducted on 1600 patients from the randomized OPTION trial. Patients were stratified into two groups: Anticoagulation (no device) and LAAC. The primary endpoint was AF recurrence, and the secondary endpoint was stroke or SE occurring after 12 months of follow-up. Patients were categorized based on AF recurrence (Yes/No) at 12 months. Arrhythmia recurrence was assessed using device interrogations in patients with cardiac implantable electronic devices and 12-lead electrocardiograms in those without devices.
Results: Of the total cohort, 803 patients (50%) underwent LAAC (41% concomitant, 59% sequential), and 797 patients (50%) were in the control group (no device). Baseline characteristics were balanced across both treatment arms. At 36-month follow-up, AF recurrence rates did not differ significantly between the groups (LAAC: 49.2% vs. No LAAC: 45.5%; P = 0.08). No difference was found between sequential and concomitant LAAC (43.6% vs. 43.9%, respectively; p=0.83). Stroke and systemic embolism rates were low and comparable between patients with and without AF recurrence (No AF: 1.00%, AF recurrence: 1.30%; p = 0.57).
Conclusion: Among patients undergoing AF ablation, LAAC (concomitant or sequential) does not impact AF ablation outcomes. The stroke/systemic embolism rate was low in all groups. Nevertheless, the trial highlights that stroke and systemic embolism remain significant risks, even in patients without AF recurrence, and should not be overlooked.
Editor-in-Chief
Kalyanam Shivkumar, MD, PhD, FACC
CME Editor
Kenneth A. Ellenbogen, MD, FACC
Authors
Arwa Younis, MD
Oussama M. Wazni, MD, MBA
Important Dates
Date of Release: February 23, 2026
Term of Approval/Date of CME/MOC Expiration: February 22, 2027